Keyphrases
Trial Results
100%
Advanced Stage
100%
Cutaneous T-cell Lymphoma
100%
Bexarotene
100%
Initial Dose
33%
Retinoids
33%
Rexinoids
33%
T Cells
16%
Headache
16%
Skin Lesions
16%
Malignancy
16%
Adenopathy
16%
Partial Response
16%
Novel Class
16%
Duration of Response
16%
Once-daily
16%
Hypertriglyceridemia
16%
Pruritus
16%
Pharmacologic Agents
16%
Orally Administered
16%
Drug Adverse Events
16%
Pancreatitis
16%
Cutaneous Tumors
16%
Specific Quality of Life
16%
San Diego
16%
Oral Therapy
16%
Hypothyroidism
16%
Retinoid Therapy
16%
Index Lesion
16%
Clinical Complete Response
16%
Point Classification
16%
Median Index
16%
Targretin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bexarotene
100%
Cutaneous T Cell Lymphoma
71%
Retinoid
42%
Adverse Event
14%
Headache
14%
Side Effect
14%
Pruritus
14%
Skin Tumor
14%
Skin Defect
14%
Lymphadenopathy
14%
Hypothyroidism
14%
Pancreatitis
14%
Hypertriglyceridemia
14%